UK Genome Editing Market Size & Outlook, 2023-2030
UK genome editing market, 2018-2030 (US$M)
Related Markets
UK genome editing market highlights
- The UK genome editing market generated a revenue of USD 668.2 million in 2023 and is expected to reach USD 2,322.3 million by 2030.
- The UK market is expected to grow at a CAGR of 19.5% from 2024 to 2030.
- In terms of segment, (crispr)/cas9 was the largest revenue generating technology in 2023.
- (CRISPR)/Cas9 is the most lucrative technology segment registering the fastest growth during the forecast period.
Genome editing market data book summary
| Market revenue in 2023 | USD 668.2 million |
| Market revenue in 2030 | USD 2,322.3 million |
| Growth rate | 19.5% (CAGR from 2023 to 2030) |
| Largest segment | (crispr)/cas9 |
| Fastest growing segment | (CRISPR)/Cas9 |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
| Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, UK accounted for 8.4% of the global genome editing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK genome editing market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 1,597.7 million by 2030.
(crispr)/cas9 was the largest segment with a revenue share of 42.37% in 2023. Horizon Databook has segmented the UK genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.
The UK genome editing market presents several potential opportunities that favor an increase in the usage of advanced genome editing tools. Numerous efforts undertaken by UK-based genome editing companies and funding initiatives supported by private & public entities drive the UK genome editing market.
In December 2020, Horizon Discovery granted two commercial licenses to Sanyou Biopharmaceuticals for its cGMP compliant CHOSOURCE platform. Sanyou was expected to utilize Horizon’s gene-edited CHO-K1 GS knockout cell line in contract research and development services and biotherapeutics pipeline development.
Adopting new rules related to genome editing creates an opportunity for the market, and the UK government is planning to change the rules related to gene editing to cut red tape and make R&D easier.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Genome Editing Market Scope
Genome Editing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK genome editing market size, by technology, 2018-2030 (US$M)
UK Genome Editing Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
